Researchers working in the clinical laboratory

OUR THERAPYClinical and Scientific Publications

Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study

Ann Surg Oncol. 2024 May 4. doi: 10.1245/s10434-024-15293-x. Epub ahead of print. PMID: 38704501.

Zager JS, Orloff M, Ferrucci PF, Choi J, et al.

Cardiovasc Intervent Radiol. 2022 Sep;45(9):1304-1313. doi: 10.1007/s00270-022-03225-9. Epub 2022 Aug 3. PMID: 35922562; PMCID: PMC9458688.

Tong TML, Samim M, Kapiteijn E, Meijer TS,et al.

Clin Exp Metastasis 40, 95–104 (2023). https://doi.org/10.1007/s10585-022-10193-4

Dewald, C.L.A., Becker, L.S., Meine, T.C. et al.

JCO 40, 9560-9560(2022). DOI:10.1200/JCO.2022.40.16_suppl.9560

Tong TML, Burgmans MC, Speetjens FM, et al.

Cardiovasc Intervent Radiol 46, 350–359 (2023). https://doi.org/10.1007/s00270-022-03338-1

Tong, T.M.L., Burgmans, M.C., Speetjens, F.M. et al.

J Clin Oncol. 2022;40:16(suppl):9510. doi: 10.1200/JCO.2022.40.16_suppl.9510

Jonathan S. Zager et al.

Melanoma Res. 2022;32(2):103–111. doi: 10.1097/CMR.0000000000000806

Modi S, Gibson T, Vigneswaran G, et al.

Cardiovasc Intervent Radiol 45, 218–222 (2022). https://doi.org/10.1007/s00270-021-02983-2

Veelken, R., Maiwald, B., Strocka, S. et al.

Nat Med 27, 152–164 (2021). https://doi.org/10.1038/s41591-020-1131-x

Yu, J., Green, M.D., Li, S. et al.

Cells. 2021;10(1):70. doi: 10.3390/cells10010070

Ferrucci PF, Cocorocchio E, Bonomo G, Varano GM, Della Vigna P, Orsi F.

Sci Immunol. 2020;5:eaba0759. doi:10.1126/sciimmunol.aba0759

Lee JC, Mehdizadeh S, Smith J, et al.

Radiol Res Pract. 2020;2020:5672048. doi: 10.1155/2020/5672048

Brüning R, Tiede M, Schneider M, et al.

Ann Surg Oncol 28, 1130–1141 (2021). https://doi.org/10.1245/s10434-020-08741-x

Meijer, T.S., Burgmans, M.C., de Leede, E.M. et al.

J Cancer Res Clin Oncol 146, 3003–3012 (2020). https://doi.org/10.1007/s00432-020-03289-5

Schönfeld, L., Hinrichs, J.B., Marquardt, S. et al.

Radiology. 2019;292(1):25–34. doi: 10.1148/radiol.2019182326

Erinjeri JP, Fine GC, Adema GJ, et al.

Cancer Imaging. 2019;19:31. doi: 10.1186/s40644-019-0218-4

Artzner C, Mossakowski O, Hefferman G, et al.

Cardiovasc Intervent Radiol 42, 841–852 (2019). https://doi.org/10.1007/s00270-019-02177-x

Meijer, T.S., Burgmans, M.C., Fiocco, M. et al.

Eur Radiol 29, 1882–1892 (2019). https://doi.org/10.1007/s00330-018-5729-z

Marquardt S, Kirstein MM, Brüning R, et al.

Eur Radiol. 2019;29:1882–1892. doi: 10.1007/s00330-018-5729-z

Karydis I, Gangi A, Wheater MJ, et al.

Adv Ther. 2016;33:2122–2138. doi: 10.1007/s12325-016-0424-4

Vogel A, Gupta S, Zeile M, et al.

OUR THERAPYClinical and Scientific Publications

Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study

Ann Surg Oncol. 2024 May 4. doi: 10.1245/s10434-024-15293-x. Epub ahead of print. PMID: 38704501.

Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis

Cardiovasc Intervent Radiol. 2022 Sep;45(9):1304-1313. doi: 10.1007/s00270-022-03225-9. Epub 2022 Aug 3. PMID: 35922562; PMCID: PMC9458688.

New Perspectives in Unresectable Cholangiocarcinoma? Evaluation of Chemosaturation with Percutaneous Hepatic Perfusion as a Palliative Treatment option

Clin Exp Metastasis 40, 95–104 (2023). https://doi.org/10.1007/s10585-022-10193-4

Safety and Efficacy of Combined Melphalan Percutaneous Hepatic Perfusion (M-PHP) and Ipilimumab Plus Nivolumab (IPI+NIVO) in Metastasized Uveal Melanoma (mUM): First Results of the Phase Ib Part of the CHOPIN Trial.

JCO 40, 9560-9560(2022). DOI:10.1200/JCO.2022.40.16_suppl.9560

Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial

Cardiovasc Intervent Radiol 46, 350–359 (2023). https://doi.org/10.1007/s00270-022-03338-1

FOCUS Phase 3 Trial Results: Percutaneous Hepatic Perfusion (PHP) with Melphalan for Patients with Ocular Melanoma Liver Metastases (PHP-OCM-301/301A).

J Clin Oncol. 2022;40:16(suppl):9510. doi: 10.1200/JCO.2022.40.16_suppl.9510

Chemosaturation with Percutaneous Hepatic Perfusion of Melphalan for Metastatic Uveal Melanoma

Melanoma Res. 2022;32(2):103–111. doi: 10.1097/CMR.0000000000000806

Repeated Percutaneous Hepatic Perfusion with Melphalan Can Maintain Long-term Response in Patients with Liver Cancers

Cardiovasc Intervent Radiol 45, 218–222 (2022). https://doi.org/10.1007/s00270-021-02983-2

Liver Metastasis Restrains Immunotherapy Efficacy via Macrophage-mediated T Cell Elimination

Nat Med 27, 152–164 (2021). https://doi.org/10.1038/s41591-020-1131-x

A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System

Cells. 2021;10(1):70. doi: 10.3390/cells10010070

Regulatory T Cell Control of Systemic Immunity and Immunotherapy Response in Liver Metastasis

Sci Immunol. 2020;5:eaba0759. doi:10.1126/sciimmunol.aba0759

Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden

Radiol Res Pract. 2020;2020:5672048. doi: 10.1155/2020/5672048

Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study

Ann Surg Oncol 28, 1130–1141 (2021). https://doi.org/10.1245/s10434-020-08741-x

Chemosaturation with Percutaneous Hepatic Perfusion is effective in Patients with Ocular Melanoma and Cholangiocarcinoma

J Cancer Res Clin Oncol 146, 3003–3012 (2020). https://doi.org/10.1007/s00432-020-03289-5

Immunotherapy and the Interventional Oncologist: Challenges and Opportunities—A Society of Interventional Oncology White Paper

Radiology. 2019;292(1):25–34. doi: 10.1148/radiol.2019182326

Chemosaturation with Percutaneous Hepatic Perfusion of Melphalan for Liver-dominant Metastatic Uveal Melanoma: a Single Center Experience

Cancer Imaging. 2019;19:31. doi: 10.1186/s40644-019-0218-4

Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems’ Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial

Cardiovasc Intervent Radiol 42, 841–852 (2019). https://doi.org/10.1007/s00270-019-02177-x

Percutaneous Hepatic Perfusion (Chemosaturation) with Melphalan in Patients with Intrahepatic Cholangiocarcinoma: European Multicentre Study on Safety, Short-term Effects and Survival

Eur Radiol 29, 1882–1892 (2019). https://doi.org/10.1007/s00330-018-5729-z

Percutaneous Hepatic Perfusion with Melphalan in Uveal Melanoma: A Safe and Effective Treatment Modality in an Orphan Disease

Eur Radiol. 2019;29:1882–1892. doi: 10.1007/s00330-018-5729-z

Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review

Adv Ther. 2016;33:2122–2138. doi: 10.1007/s12325-016-0424-4